Yolanda Barbachano has been appointed as Head of Statistics for Quanticate.
Massive Bio announced the addition of two executives to its C-suite: Özgür “Oz” Huner as their first Chief Product Officer, and Erkan Terzi has been promoted to Chief Marketing Officer.
Encapsia announced the appointment of Francis Destin as its new Chief Operating Officer.
Dawn Sauro has been named as Elligo’s Chief Operating Officer.
Trialbee announced the addition of Kristopher Sarajian as their new Vice President of Marketing.
Greenphire has appointed Owen Newman as the Chief Financial Officer.
Emmes appointed Matt Honan as Vice President and Head of Corporate Development.
NNIT has received its recertification as a Veeva Premiere Services Partner – Development Cloud.
Suvoda LLC surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Empower Sponsor Success with Insights from Sites
October 3rd 2024Are you tired of clinical trial technology that slows down processes? Are your sites looking for more intuitive solutions? At YPrime, we’ve taken a deep dive into site experiences and perspectives, sharing ways to bridge the gap between sponsors, sites, and patients, to foster a more efficient clinical trial process.